Updated:
Phathom Pharmaceuticals
Phathom Pharmaceuticals was formed in 2019 by a syndicate including Frazier Healthcare Partners and Medicxi, structuring a deal with Takeda to acquire US...
Phathom Pharmaceuticals
Phathom Pharmaceuticals was formed in 2019 by a syndicate including Frazier Healthcare Partners and Medicxi, structuring a deal with Takeda to acquire US and European rights to vonoprazan. The founding transaction gave Takeda a significant equity stake, aligning a global pharma incumbent with a newly capitalized, independent development company. CEO Terrie Curran, former head of global gastroenterology at Allergan, brought deep commercial GI expertise to a pipeline built on a single molecular platform. The firm's strategy focuses on developing vonoprazan across erosive esophagitis, H. pylori eradication, and non-erosive GERD indications. Phathom runs a fully integrated model — managing clinical trials, regulatory submissions, and the build-out of a proprietary sales force rather than outsourcing to a contract sales organization. In May 2022, the FDA approved Voquezna Triple Pak and Voquezna Dual Pak for H. pylori, making it the first new drug class approved for this infection in over a decade. The company announced a commercial partnership with Cardinal Health for third-party logistics services (per the firm, 2023). Its operational geography is concentrated in the United States, with a licensing footprint that extends to European markets through Takeda. As of its most recent public filings, Phathom employed a compact team of approximately 200 professionals, headquartering in Florham Park, New Jersey. The company raised $190 million in an upsized public offering in May 2022 to fund the Voquezna launch (per Fierce Biotech, 2022). In September 2024, Phathom reported third-quarter Voquezna net revenue of $11.2 million, more than double the prior quarter, signaling early prescription uptake. Adjacent vehicles are limited to the parent entity — no venture studio, family trust, or philanthropic foundation separates the commercial mission. Phathom's structural edge lies in its drug formulation exclusivity. Unlike traditional proton-pump inhibitors that are generic and widely commoditized, vonoprazan is covered by method-of-use patents extending into the 2030s. The firm is a de-risked, single-asset biotech in revenue, not clinical-trial mode — a rare structure where a reverse spinout bypasses preclinical risk entirely and moves directly into market creation against a massive, entrenched standard of care.
General information
Firm type
Asset Manager
Year founded
2019
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Florham Park
Corporate office
Florham Park, NJ, United States
Principals
Terrie Curran
President and Chief Executive Officer
Todd Branning
Chief Financial Officer
Sector focus
Frequently asked questions
How is Phathom Pharmaceuticals structured as an entity?
Phathom is a publicly traded commercial-stage biopharmaceutical company (Nasdaq: PHAT). It was formed in 2019 through a unique transaction with Takeda Pharmaceutical, acquiring US and European rights to vonoprazan rather than in-licensing the molecule. Takeda remains a significant minority shareholder, but Phathom operates independently with its own management, sales force, and R&D function.
What makes Phathom's lead asset, Voquezna, different from existing acid-reflux drugs?
Voquezna (vonoprazan) is a potassium-competitive acid blocker, a novel mechanism distinct from the proton-pump inhibitors (PPIs) like omeprazole that have dominated the market for 30 years. It acts faster, does not require activation by stomach acid, and has a longer duration of acid suppression than PPIs. The FDA approved it for H. pylori in 2022 and erosive esophagitis in 2023.
Who runs investment decisions at Phathom?
As a public operating company, capital allocation decisions rest with the executive team led by CEO Terrie Curran and CFO Todd Branning, under board oversight. The board includes representatives from founding investors Frazier Healthcare Partners and Medicxi, who participated in Phathom's initial capital raising and subsequent public follow-on offerings.
What investment stages does Phathom typically target?
Phathom is not an investment firm — it is an operating biopharmaceutical company that deploys capital directly into drug development and commercialization. Its model is best understood as late-stage and commercial-stage drug development: it acquired an already human-tested molecule from Takeda and funded its own Phase 3 trials through to FDA approval and national product launch.
What is Phathom's known posture on co-investments alongside external partners?
Phathom has not entered traditional co-investment structures. Its primary external relationship is the foundational asset acquisition from Takeda, which included milestone and royalty obligations rather than shared equity risk. The company raised follow-on capital through public equity offerings, most notably a $190 million raise in 2022 (per Fierce Biotech, 2022).
Where does the underlying capital for Phathom's launch come from?
Phathom was initially capitalized by a syndicate of healthcare-dedicated venture firms including Frazier Healthcare Partners and Medicxi, with additional backing from Takeda in the form of the vonoprazan asset contribution. It subsequently accessed public markets via an IPO in 2019 and a follow-on offering in 2022. As of late 2024, it generates product revenue from Voquezna prescriptions.
Which sectors does Phathom explicitly avoid?
Phathom is therapeutically focused on gastrointestinal disease and does not operate outside of gastroenterology. It has no oncology, neurology, or rare-disease programs. The company's negative screen is effectively any therapeutic area beyond acid-related GI disorders, where vonoprazan has proven clinical data.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: